PDS Biotechnology Corp

PDSB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-34.5M $-37.6M $-42.9M $-40.9M $-16.9M $-14.8M $-7.0M $-3.8M
Depreciation & Amortization $15.6K $98.4K $69.1K
Depreciation $21.8K $21.1K $17.4K $86 $5.4K $15.6K $98.4K $23.3K
Amortization
Stock-Based Compensation $4.1M $6.8M $7.6M $5.2M $4.1M $432.3K $3.1M $866.8K
Net Cash from Operating Activities $-27.8M $-35.0M $-33.6M $-25.7M $-12.5M $-13.1M $-18.1M $-1.6M
Investing Activities
Capital Expenditures $0 $29.0K $0 $0
Business Acquisitions
Net Cash from Investing Activities $0 $-29.0K $0 $0 $29.4M $0
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $12.8M $20.2M $16.4M $34.3M $48.9M $29.8M $750.0K $1.5M
Net Change in Cash $-53.4M
Free Cash Flow $-27.8M $-35.1M $-33.6M $-1.6M
← Newer Page 1 of 2 Older →